Life-threatening laryngeal oedema in a pregnant woman with hereditary angioedema. by McGlinchey, P. G. et al.
The UlsterMedical Journal, Volume 69, No. 1, pp. 54-57, May 2000.
Case Report
Life-threatening laryngeal oedema in a pregnant woman
with hereditary angioedema
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Hereditary angioedema is an unusual condition
thathasbeenassociatedwithahighmortalityrate
during acute attacks. The disease is feltto have a
benign course in pregnancy, but some reports
indicate a worsening of attacks in pregnant
women. Acase ofapregnantwomanwithknown
hereditary angioedema presenting with life-
threatening laryngeal oedema is reported, and is
followed by a discussion ofthe disease, its links
with sex hormones and areview ofthe literature.
CASE REPORT A 26-year-old primigravidum
woman, pregnant at 25 weeks gestation, was
admittedwithatwo-hourhistoryofasensationof
swelling in her neck. She and her sisterhad been
diagnosedashavingtypeIhereditaryangioedema
four years previously through family screening
following the discovery ofa similar diagnosis in
hermother. Thisdiagnosis wasmadeonthebasis
of serum analysis revealing decreased levels of
Cl inhibitor (<0.04 g/l; normal range 0.28-0.50
g/l), functionalCl inhibitor(7% ofnormallevels)
and C4, the fourth component of complement
(<0.06g/l; normalrange0.2-0.5 g/l) andnormal
levels ofC3, thethird componentofcomplement
(1.03 g/l; normal range 0.5-1.2 gIl). Her health
prior to her pregnancy had been good with only
threeshort-livedepisodesofangioedemaaffecting
herhandsaloneandoneepisodeoffacialswelling
following a dental procedure. Since becoming
pregnant, there had been an increase in the
frequency and duration of the angioedematous
episodes, with swelling in her arms, legs and
shoulder occurring, on average, once per week.
She was not dyspnoeic and had no foot or arm
swelling; her sole complaint was the swelling
sensation in her neck which was giving rise to
some difficulty in swallowing. On examination
she appeared comfortable; her temperature was
36.20 C, with a heart rate of96 beats perminute,
blood pressure of 108/58 mmHg and oxygen
saturations of 98% on room air. Cardiovascular
and respiratory examinations were normal and
abdominal examination was consistent with
pregnancy of 25 weeks gestation. There was no
evidence of swelling in her throat, neck or
peripheries.
She was treated with 200 mg of hydrocortisone
and 10 mg of chlorpheniramine intravenously
and admitted for observation.
Three hours later she felt that her breathing had
become more difficult. Examination of her
oropharynx revealed swelling of the soft palate
with the vocal cords moving and the airway
intact. Observations and clinical examination
otherwise were still normal.
A further three hours later she developed
respiratory distress with stridor. Examination
revealedpharyngealswellingwiththevocalcords
viewed only with difficulty. She received one
unit of fresh frozen plasma with some
improvementofhersymptoms andsigns andwas
thengiven2000unitsofC1 inhibitorconcentrate,
which led to complete resolution within 30
minutes.
Royal Victoria Hospital, Belfast.
P G McGlinchey, MB, BCh, BAO, MRCP, Senior House
Officer in General Medicine.
K Golchin, MB, BCh, BAO, FRCS, SeniorHouse Officer
in Otorhinolaryngology.
DRMcCluskey, MD,FRCP,FRCPI,ConsultantinClinical
Immunology.
Correspondence to Dr McGlinchey.
© The Ulster Medical Society, 2000.Hereditary angioedema andpregnancy 55
Shehadnofurtherproblems whileinhospitaland
was discharged five days later on tranexamic
acid. The rest of the pregnancy was uneventful.
Thedeliverywasvaginalanduncomplicatedwith
prophylactic administration of Cl inhibitor
concentrate 1000units onthedayofdelivery and
the following two days. A healthy male infant
was born. To date he has not been screened for
hereditary angioedema.
DISCUSSION
Hereditary angioedema (HAE) is an unusual
condition characterised by recurrent episodes of
localised, well-circumscribed, non-pitting
oedema. It may affect any part of the body, but
more commonly involves the extremities, trunk,
face, throat and the abdominal viscera where it
causes pain. Involvement of the larynx is
particularly dangerous, with a high mortality
rate.1'2 Morerecent clinical observations include
symptomsofurinarytractinfectioninwomen, an
increase in spontaneous abortions andpremature
labour, and more frequently reported heartburn
and rheumatic complaints.3
The hereditary nature of the disease was first
described by Osler in 1888,4 and it is transmitted
in a Mendelian autosomal dominant manner.5
Investigation of the biochemical abnormality
underlying HAE began with the identification
andcharacterisationofCl-inhibitor.6C -inhibitor
isana2globulinthatblockstheesterolyticactivity
ofthefirstcomponentoftheclassicalcomponent
pathway.7 It also has inhibitory actions on the
fibrinolytic and kallikrein-kinin systems.8
Subsequently a deficiency of this serum protein
in individuals with HAE was discovered.9 There
are two forms of HAE, type I in which there is
both absent or decreased Cl-inhibitor antigenic
levels anddecreasedfunctionalactivity, andtype
II, in which a dysfunctional protein is produced
leading to normal Cl-inhibitor antigenic levels
but markedly reduced functional activity.10 Both
forms have decreased levels of the fourth
component of complement. In acute attacks of
HAE, the deficiency of Cl-inhibitor allows
unrestricted activation of the complement,
fibrinolytic and kallikrein-kinin systems with
increasedgenerationofplasmin" I andbradykinin12
whichcauseslocalisedoedemathroughenhanced
vascularpermeability andextravasationoffluid.'3
TheCl1 inhibitor gene is located on chromosome
11 (p.1 1.2-q-13),wheremutationsinthestructural
generegionareresponsibleforHAE."4Aparticular
region of the gene contains direct repeats of the
triplet CAA, making it susceptible to mutation."5
There is considerable genetic heterogeneity in
the disease, with a number of mutations
described.16-20
Theinitial presentation ofHAEis typically early
in life, with over 50% having their first attack in
the first decade of life.8 21'22 It affects a wide
diversity of ethnic groups.2' The most common
precipitants of an acute attack are trauma,
emotion,' insect stings and food.2
HAE appears to follow a benign course in
pregnancy.8,21 However, case reports have
describedanincreaseintheincidenceandseverity
of attacks,23-25 while labial oedema caused by
vaginal delivery has been the first clinical
presentation of the disease.26 Indeed, vaginal
delivery leading to perineal oedema and
hypovolaemia has caused maternal mortality.27
Cautionis advisedinmaking adiagnosis ofHAE
in pregnancy, as levels of C1 inhibitor may be
decreased in normal pregnant women, returning
to normal levels after delivery.28
The role of oestrogen in HAE has been debated.
An increase in attacks has been reported during
menstruation,8 22withoralcontraceptives causing
greater frequency and severity of attacks.2'8'29
ThemeanvaluesofbothCI inhibitoractivityand
antigentitresaresignificantlydecreasedinnormal
women using oral contraceptives compared to
non-users.29 Familial, oestrogen-linked angio-
edema attacks not caused by C1 inhibitor
deficiency have also been described.30
The treatment of HAE has been traditionally
divided into three groups i.e. treatment of acute
attacks, long-term prophylaxis and short-term
prophylaxis. Attempted therapy with adrenaline,
antihistaminic agents or corticosteroids has no
roleorbenefitinpatientswithHAE.8Themainstay
of the treatment of acute episodes of HAB is
replacement therapy, successfully used in the
therapy ofother serum protein deficiencies such
as haemophilia and hypogammaglobulinaemia.
Infusion of fresh frozen plasma has been shown
to be beneficial,3' although concerns exist that it
maytheoreticallyworsentheattack.32Cl1 inhibitor
concentrate has also been shown to be safe and
effective in the resolution of acute episodes.33
Givenindosesof500to 1000unitsintravenously,
oedema begins to resolve within 30 minutes to
two hours ofinjection, with complete remission
within 24 hours.32
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Agentseffectiveinlong-termprophylaxisinclude
attenuated androgens and antifibrinolytics. The
main androgen used is danazol, which has been
shown to decrease the severity and frequency of
attacks, with biochemical assays ofCI inhibitor
and C4 returning to normal levels.34-36 The doses
used should be the minimum needed to control
attacks, as significant dose-related adverse
reactions have been reported, including weight
gain, myalgia, headaches, microscopic
haematuria, altered liver function tests, anxiety,
alteredlibido, alopecia, dizziness andnausea.38 39
Danazol also has virilizing effects on a female
foetusifusedinpregnancy.37Stanozololisanother
androgen with a similar efficacy and side effect
profile.40 Two antifibrinolytic agents, £-
aminocaproic acid and transexamic acid are
reportedto assistinthe control ofHAE, buthave
anumberofserious sideeffectsincludingmuscle
necrosis andapotentialthrombotictendency.41'42
Fresh frozen plasma has also been used forlong-
term prophylaxis in a pregnant woman with
HAE.43
Short-termprophylaxisisimportantinindividuals
withknownHAEwhoareundergoingprocedures
which can potentially precipitate an attack,
including surgery, dental work or labour.
Attenuatedandrogensmaybeusedinpregnancy,44
but there is the potential risk of virilization of a
femalefoetus, andthisriskhasbeencited, atleast
in part, as an indication for termination of
pregnancy in a woman with HAE.4s Fresh frozen
plasma46 and C1 inhibitor concentrate22'47 have
both been advocated for short-term prophylaxis
in these situations.
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